VCI Wealth Management LLC Grows Stock Holdings in Abbott Laboratories $ABT

Posted by Brenda Bartman on Aug 25th, 2026

VCI Wealth Management LLC grew its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 45.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,788 shares of the healthcare product maker’s stock after purchasing an additional 8,660 shares during the period. VCI Wealth Management LLC’s holdings in Abbott Laboratories were worth $2,522,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on ABT shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Citigroup raised their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.67.

View Our Latest Report on ABT

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $116.70 on Tuesday. The company’s 50 day simple moving average is $100.64 and its 200-day simple moving average is $100.03. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a market capitalization of $201.94 billion, a price-to-earnings ratio of 37.77, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor
Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott
Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement
Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now?
Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.